drugset / Trial / NCT01220024

Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

NCT01220024

Phase 2 Completed 50 enrolled Innocoll Premier Research · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess pain intensity for the first 72 hrs after after aggravated movement (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.

Timeline

Start
2010-12-02
Primary completion
2011-05-18
Completion
2011-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 200 mg Other

Indications

No indication recorded.